Literature DB >> 15821961

Diagnosis of Alzheimer's disease using brain perfusion SPECT and MR imaging: which modality achieves better diagnostic accuracy?

Takao Kubota1, Yo Ushijima, Kei Yamada, Chio Okuyama, Osamu Kizu, Tsunehiko Nishimura.   

Abstract

PURPOSE: The purpose of this study was to compare the accuracy of MR imaging and brain perfusion single-photon emission tomography (SPECT) in diagnosing Alzheimer's disease (AD).
METHODS: The transaxial section display of brain perfusion SPECT, three-dimensional stereotactic surface projection (3D-SSP) SPECT image sets, thin-section MR imaging of the hippocampus and perfusion MR imaging were evaluated in 66 subjects comprising 35 AD patients and 31 subjects without AD. SPECT and MR imaging were visually interpreted by two experts and two novices, and the diagnostic ability of each modality was evaluated by receiver operating characteristic (ROC) analysis.
RESULTS: In the experts' interpretations, there was no significant difference in the area under the ROC curve (Az) between 3D-SSP and thin-section MR imaging, whereas the Az of transaxial SPECT display was significantly lower than that of 3D-SSP (3D-SSP: 0.97, thin-section MR imaging: 0.96, transaxial SPECT: 0.91), and the Az of perfusion MR imaging was lowest (0.63). The sensitivity and specificity of each modality were, respectively, 80.0% and 96.8% for 3D-SSP, 77.1% and 96.8% for thin-section MR imaging, 60.0% and 93.5% for transaxial SPECT display and 34.3% and 100% for perfusion MR imaging. In the novices' interpretations, the Az, sensitivity and specificity of 3D-SSP were superior to those of thin-section MR imaging.
CONCLUSION: Thin-section hippocampal MR imaging and 3D-SSP image sets had potentially equivalent value for the diagnosis of AD, and they were superior to transaxial SPECT display and perfusion MR imaging. For avoidance of the effect of interpreters' experience on image evaluation, 3D-SSP appears to be optimal.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15821961     DOI: 10.1007/s00259-004-1704-9

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  38 in total

1.  MRI of entorhinal cortex in mild Alzheimer's disease.

Authors:  M Bobinski; M J de Leon; A Convit; S De Santi; J Wegiel; C Y Tarshish; L A Saint Louis; H M Wisniewski
Journal:  Lancet       Date:  1999-01-02       Impact factor: 79.321

Review 2.  Neuroimaging in dementia with Lewy bodies: metabolism, neurochemistry, and morphology.

Authors:  Satoshi Minoshima; Norman L Foster; Eric C Petrie; Roger L Albin; Kirk A Frey; David E Kuhl
Journal:  J Geriatr Psychiatry Neurol       Date:  2002       Impact factor: 2.680

3.  Diffusion and perfusion MR imaging in cases of Alzheimer's disease: correlations with cortical atrophy and lesion load.

Authors:  A Bozzao; R Floris; M E Baviera; A Apruzzese; G Simonetti
Journal:  AJNR Am J Neuroradiol       Date:  2001 Jun-Jul       Impact factor: 3.825

4.  Alzheimer disease: improved visual interpretation of PET images by using three-dimensional stereotaxic surface projections.

Authors:  J H Burdette; S Minoshima; T Vander Borght; D D Tran; D E Kuhl
Journal:  Radiology       Date:  1996-03       Impact factor: 11.105

5.  Patterns of cerebral atrophy in dementia with Lewy bodies using voxel-based morphometry.

Authors:  E J Burton; G Karas; S M Paling; R Barber; E D Williams; C G Ballard; I G McKeith; P Scheltens; F Barkhof; J T O'Brien
Journal:  Neuroimage       Date:  2002-10       Impact factor: 6.556

Review 6.  Functional brain imaging in the dementias: role in early detection, differential diagnosis, and longitudinal studies.

Authors:  Michael D Devous
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-09-25       Impact factor: 9.236

7.  Longitudinal evaluation of early Alzheimer's disease using brain perfusion SPECT.

Authors:  D Kogure; H Matsuda; T Ohnishi; T Asada; M Uno; T Kunihiro; S Nakano; M Takasaki
Journal:  J Nucl Med       Date:  2000-07       Impact factor: 10.057

8.  Language comprehension and regional cerebral defects in frontotemporal degeneration and Alzheimer's disease.

Authors:  M Grossman; F Payer; K Onishi; M D'Esposito; D Morrison; A Sadek; A Alavi
Journal:  Neurology       Date:  1998-01       Impact factor: 9.910

9.  Alzheimer's disease and frontotemporal dementia are differentiated by discriminant analysis applied to (99m)Tc HmPAO SPECT data.

Authors:  P Charpentier; I Lavenu; L Defebvre; A Duhamel; P Lecouffe; F Pasquier; M Steinling
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-11       Impact factor: 10.154

10.  Value of (99m)Tc-ECD SPET for the diagnosis of dementia with Lewy bodies.

Authors:  Jacques Pasquier; Bernard F Michel; Isabelle Brenot-Rossi; Nathalie Hassan-Sebbag; Richard Sauvan; Jean Louis Gastaut
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-07-31       Impact factor: 9.236

View more
  1 in total

Review 1.  The Legacy of the TTASAAN Report-Premature Conclusions and Forgotten Promises: A Review of Policy and Practice Part I.

Authors:  Dan G Pavel; Theodore A Henderson; Simon DeBruin
Journal:  Front Neurol       Date:  2022-03-28       Impact factor: 4.086

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.